Due to its prevalence and negative impacts on both economy and society, the diabetes mellitus (DM) has emerged as a worldwide concern. In light of this, the label-free quantification proteomics (LFQ) and diabetic marker selection methods have been applied to elucidate the underlying mechanisms associated with insulin resistance, explore novel protein biomarkers, and discover innovative therapeutic protein targets.
The purpose of this manuscript is to review and analyze the recent computational advances and development of label-free quantification and diabetic marker selection in diabetes proteomics.Web of Science database, PubMed database and Google Scholar were utilized for searching label-free quantification, computational advances, feature selection and diabetes proteomics.In this study, we systematically review the computational advances of label-free quantification and diabetic marker selection which be applied to get understanding of DM pathological mechanisms.
Firstly, different popular quantification measurements and proteomic quantification tools which have been applied to the diabetes studies are comprehensively discussed. Secondly, a number of popular manipulation methods including transformation, pretreatment (centering, scaling, and normalization), missing value imputation methods and a variety of popular feature selection techniques applied to diabetes proteomic data are overviewed with objective evaluation on their advantages and disadvantage.
 GlyH-101 |
| B1087-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 148.00 |
|
Description: GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM. |
GlyH-101 |
| B1087-50 |
ApexBio |
50 mg |
EUR 659.00 |
|
Description: GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM. |
 Sulforhodamine 101 |
| 80101 |
Biotium |
500MG |
EUR 236.00 |
|
Description: Minimum order quantity: 1 unit of 500MG |
 CUDC-101 |
| A4092-10 |
ApexBio |
10 mg |
EUR 137.00 |
|
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
CUDC-101 |
| A4092-200 |
ApexBio |
200 mg |
EUR 943.00 |
|
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
CUDC-101 |
| A4092-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 158.00 |
|
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
CUDC-101 |
| A4092-50 |
ApexBio |
50 mg |
EUR 386.00 |
|
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
CUDC-101 |
| A4092-S |
ApexBio |
Evaluation Sample |
EUR 81.00 |
|
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
 ARP 101 |
| A4433-5 |
ApexBio |
5 mg |
EUR 334.00 |
|
Description: ARP 101 is a selective MMP-2 inhibitor with IC50 value of 0.81nM. |
 AT-101 |
| A3196-10 |
ApexBio |
10 mg |
EUR 171.00 |
|
Description: AT101, a natural product from cottonseed with a BH3-mimetic structure, was identified as a small molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 that potently induces apoptosis in various cancer cell lines [1]. |
AT-101 |
| A3196-50 |
ApexBio |
50 mg |
EUR 432.00 |
|
Description: AT101, a natural product from cottonseed with a BH3-mimetic structure, was identified as a small molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 that potently induces apoptosis in various cancer cell lines [1]. |
 LOXO-101 |
| B6176-100 |
ApexBio |
100 mg |
EUR 696.00 |
|
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival. |
LOXO-101 |
| B6176-25 |
ApexBio |
25 mg |
EUR 290.00 |
|
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival. |
LOXO-101 |
| B6176-5 |
ApexBio |
5 mg |
EUR 128.00 |
|
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival. |
 Trap 101 |
| B7084-10 |
ApexBio |
10 mg |
EUR 373.00 |
Trap 101 |
| B7084-50 |
ApexBio |
50 mg |
EUR 1363.00 |
Sulforhodamine 101 |
| B7762-100 |
ApexBio |
100 mg |
EUR 137.00 |
Sulforhodamine 101 |
| B7762-250 |
ApexBio |
250 mg |
EUR 257.00 |
Sulforhodamine 101 |
| B7762-500 |
ApexBio |
500 mg |
EUR 390.00 |
 UCF 101 |
| C4437-10 |
ApexBio |
10 mg |
EUR 186.00 |
|
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli. |
UCF 101 |
| C4437-25 |
ApexBio |
25 mg |
EUR 354.00 |
|
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli. |
UCF 101 |
| C4437-5 |
ApexBio |
5 mg |
EUR 145.00 |
|
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli. |
 AS 101 |
| B7830-5 |
ApexBio |
5 mg |
EUR 171.00 |
|
Description: Ammonium tri-chloro(dioxoethylene-O,O?-)tellurate (AS-101), an anti?IL-10 compound, is a nontoxic immunomodulator.AS101 (0.43222.5 ?g/ml) decreased IL-10 production in a dose-dependent manner. |
 UFP-101 |
| B5128-1 |
ApexBio |
1 mg |
EUR 583.00 |
 miRZip-101 anti-miR-101 microRNA construct |
| MZIP101-PA-1 |
SBI |
Bacterial Streak |
EUR 684.00 |
|
|
 KHS 101 hydrochloride |
| B7717-10 |
ApexBio |
10 mg |
EUR 318.00 |
KHS 101 hydrochloride |
| B7717-50 |
ApexBio |
50 mg |
EUR 1162.00 |
 LOXO-101 sulfate |
| B2545-25 |
Biovision |
|
EUR 414.00 |
LOXO-101 sulfate |
| B2545-5 |
Biovision |
|
EUR 196.00 |
Finally, the guidelines for the efficient use of the computation-based LFQ technology and feature selection methods in diabetes proteomics are proposed.In summary, this review provides guidelines for researchers who will engage in proteomics biomarker discovery and by properly applying these proteomic computational advances, more reliable therapeutic targets will be found in the field of diabetes mellitus.
